CN111551742B - Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis - Google Patents
Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis Download PDFInfo
- Publication number
- CN111551742B CN111551742B CN202010371676.7A CN202010371676A CN111551742B CN 111551742 B CN111551742 B CN 111551742B CN 202010371676 A CN202010371676 A CN 202010371676A CN 111551742 B CN111551742 B CN 111551742B
- Authority
- CN
- China
- Prior art keywords
- ala
- val
- tuberculosis
- leu
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides application of products for detecting the levels of an anti-Rv 0389 antibody, an anti-Rv 1408 antibody and an anti-Rv 2097c antibody in a sample in preparation of products for identifying, diagnosing and/or screening latent tuberculosis infection. The method provided by the invention can be used for simultaneously detecting the serum antibody response levels of three different mycobacterium tuberculosis proteins, so that tuberculosis latent infection patients and active tuberculosis patients can be better identified and diagnosed, the sensitivity is higher, and the specificity is better.
Description
The present application is a divisional application of the invention patent application with the application number 2016112574947, the application date of which is 2016, 12 and 30.
Technical Field
The invention relates to the field of biological medicine, in particular to application of mycobacterium tuberculosis proteins in preparation of products for diagnosing tuberculosis latent infection and/or active tuberculosis.
Background
After the human body is infected with the mycobacterium tuberculosis, about 10% of people develop active tuberculosis, but 90% of people do not develop active tuberculosis, but the in-vivo tuberculosis is not completely cleared, but is hidden in the human body, which is called tuberculosis hidden infection, the people do not have any clinical symptoms, most of people do not develop the active tuberculosis in their life, and only 5% -10% of people can cause the occurrence of tuberculosis when the immunity of the human body is reduced. At present, about 1/3 of people in the whole world are infected with tubercle bacillus, and the number of people with latent infection is numerous, so that the people with latent infection are required to be monitored, and medicine treatment is timely given when the infection state changes, so that early detection and early treatment are realized, the worsening of the illness state can be prevented, the treatment time and the side effect caused by medicine treatment can be reduced, and the spreading of tuberculosis can be reduced. Therefore, detection and identification of two states after tuberculosis infection are very important for prevention and treatment of tuberculosis.
There are many methods for detecting tubercle bacillus infection at present, including tubercle bacillus skin test (TST), gamma-interferon release test (IGRA), traditional sputum acid fast bacteria smear, quick culture of mycobacterium, amplification of tuberculosis specific nucleic acid fragment (quantitative and qualitative), etc. TST is skin allergy, and the service time is long, is mainly used for outpatient screening, and although the test is simple and easy to implement, when the tuberculosis infection condition is detected, the same result appears in BCG inoculation, natural infection cannot be identified, the specificity is not strong, and in addition, tuberculosis latent infection and active tuberculosis cannot be identified. The gamma-interferon release assay (IGRA) is mainly used for detecting cellular immune responses, but can exclude the influence of bacillus calmette-guerin inoculation, and can not distinguish latent infection patients from active tuberculosis patients, and can not distinguish patients after treatment from symptomatic infection patients. The traditional sputum acid-fast bacteria smear, mycobacterium rapid culture and the like are mainly used for detecting active tuberculosis patients, have no meaning for judging the latent infection state, and can not find bacteriological evidence for active tuberculosis patients with atypical clinical symptoms. It would therefore be of great value to find a method that would accurately identify latent infection and active tuberculosis.
Based on the difference of host protective immune response caused after tubercle bacillus infection, the search of serum markers for distinguishing latent infection and active tuberculosis has good application prospect. The serological diagnosis of antigen-antibody reaction is focused on the ease and rapidity of sample acquisition, and some specific antigens of mycobacterium tuberculosis are currently used for serological diagnosis of tuberculosis infection, such as secreted protein antigen: antigen 85 complex antigens, i.e., ag85A, ag85B and Ag85C, etc.; lipoprotein antigen: a 16kDa,27kDa,38kDa antigen, etc.; glycolipid antigen: lipoarabinomannan antigen, tubercle bacillus saccharide lipoantigen, etc.; however, in practical use, the antigens have low positive detection rate and cross immunity with other mycobacteria, and have certain value in general investigation, treatment effect monitoring, prognosis judgment and recurrence prompting of high-risk groups, but cannot be used for the definite diagnosis of latent mycobacterium tuberculosis infection at present.
Therefore, it is very important to find a new method and a marker that can accurately diagnose tuberculosis latent infectors and active tuberculosis patients.
Disclosure of Invention
The invention aims to solve the technical problems that in the prior art, products for differential diagnosis of tuberculosis latent infected persons and/or active tuberculosis have low positive detection rate and latent mycobacterium tuberculosis infection cannot be differential diagnosed, and provides application of mycobacterium tuberculosis protein in preparation of products for diagnosis of tuberculosis latent infected persons and/or active tuberculosis.
In order to solve the technical problems, the technical scheme provided by one aspect of the invention is as follows:
use of a product for detecting the level of an anti-Rv 0389 antibody, an anti-Rv 1408 antibody and/or an anti-Rv 2097c antibody in a sample for the preparation of a product for the identification, diagnosis and/or screening of latent tuberculosis infection and/or active tuberculosis.
In the technical scheme of the invention, any product for detecting the level of the anti-Rv 0389 antibody, the anti-Rv 1408 antibody and/or the anti-Rv 2097c antibody in a sample can be used for preparing a product for identifying, diagnosing and/or screening latent tuberculosis infection and/or active tuberculosis.
Preferably, the product for detecting the level of the anti-Rv 0389 antibody, the anti-Rv 1408 antibody and/or the anti-Rv 2097c antibody in the sample contains an Rv0389 protein, an Rv1408 protein and/or an Rv2097c protein.
More preferably, the Rv0389 protein is shown in SEQ ID No.1, or one or more amino acid residues in the amino acid sequence shown in SEQ ID No.1 are modified to have the same function as the protein shown in SEQ ID No. 1; the Rv1408 protein is shown in SEQ ID NO.2, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.2 are modified to have the same function as the protein shown in SEQ ID NO. 2; the Rv2097c protein is shown as SEQ ID NO.3, or one or more amino acid residues in the amino acid sequence shown as SEQ ID NO.3 are modified to have the same function as the protein shown as SEQ ID NO. 3.
The term "engineering" as described above may use any prior art method of engineering proteins, including, but not limited to, substitution and/or addition and/or deletion of amino acid residues, to form derivatives of the original protein.
Preferably, the assay may be any suitable assay known in the art, but preferably, the assay may be an enzyme-linked immunosorbent assay, an agglutination assay, a precipitation assay, an E-garland assay, a small phagocytosis assay, an immunofluorescence assay, a colloidal gold immunochromatography assay, a spot gold immunodiafiltration assay and/or an electrochemiluminescence assay. More preferably, in one embodiment of the invention, the method of detection is an enzyme-linked immunosorbent assay.
Preferably, the sample may be any suitable sample obtained from the subject to be tested. But preferably the sample comprises serum, plasma, saliva, urine, hydrothorax and/or cerebrospinal fluid. More preferably, in one embodiment of the invention, the sample is serum.
Another aspect of the present invention is to provide a marker composition for identifying, diagnosing and/or screening for latent tuberculosis infection and/or active tuberculosis, the marker composition consisting of an anti-Rv 0389 antibody, an anti-Rv 1408 antibody and/or an anti-Rv 2097c antibody;
wherein, the Rv0389 is shown in SEQ ID NO.1, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.1 are modified to have the same function as the protein shown in SEQ ID NO. 1; the Rv1408 is shown as SEQ ID NO.2, or one or more amino acid residues in the amino acid sequence shown as SEQ ID NO.2 are modified to have the same function as the protein shown as SEQ ID NO. 2; the Rv2097c is shown as SEQ ID NO.3, or one or more amino acid residues in the amino acid sequence shown as SEQ ID NO.3 are modified to have the same function as the protein shown as SEQ ID NO. 3.
In another aspect, the invention provides the use of a marker composition as described above for the preparation of a product for the identification, diagnosis and/or screening of latent tuberculosis infection and/or active tuberculosis.
In another aspect of the invention there is provided a kit for identifying, diagnosing and/or screening for latent tuberculosis infection and/or active tuberculosis, the kit comprising an Rv0389 protein, an Rv1408 protein and/or an Rv2097c protein.
Preferably, the Rv0389 protein is shown in SEQ ID NO.1, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.1 are modified to have the same function as the protein shown in SEQ ID NO. 1; the Rv1408 protein is shown in SEQ ID NO.2, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.2 are modified to have the same function as the protein shown in SEQ ID NO. 2; the Rv2097c protein is shown as SEQ ID NO.3, or one or more amino acid residues in the amino acid sequence shown as SEQ ID NO.3 are modified to have the same function as the protein shown as SEQ ID NO. 3.
The Rv0389 protein, rv1408 protein and/or Rv2097c protein contained in the above kit may be in any form, including but not limited to direct protein samples, and forms of immobilizing proteins on a carrier such as a detection chip.
The kit comprises at least kit instructions in addition to the Rv0389 protein, the Rv1408 protein and/or the Rv2097c protein.
Criteria for the results are described in the specification: and (3) using three proteins for combined detection, if at least 2 antibodies in the anti-Rv 0389 antibody, the anti-Rv 1408 antibody and/or the anti-Rv 2097c antibody are positive in the detection result of the sample to be detected, judging that the sample to be detected is positive in active tuberculosis, otherwise, judging that the sample to be detected is latent tuberculosis infection.
In another aspect, the invention provides the use of a kit as described above for the preparation of a product for the identification, diagnosis and/or screening of latent tuberculosis infection and/or active tuberculosis.
The beneficial effects of the invention are as follows:
the invention can detect the response level of three different mycobacterium tuberculosis protein serum antibodies at the same time, thereby being capable of better distinguishing and diagnosing tuberculosis latent infection patients and active tuberculosis patients, and having higher sensitivity and better specificity.
Drawings
FIG. 1 is a statistical chart showing ELISA detection of expression levels of anti-Rv 0389 antibody, anti-Rv 1408 antibody and anti-Rv 2097c antibody in serum of tuberculosis latent infected person (n=93) and active tuberculosis patient (n=92)
FIG. 2 is a ROC graph of antibodies corresponding to the combined detection of three antigens;
DESCRIPTION OF THE SEQUENCES
SEQ ID NO.1 is the amino acid sequence of the Rv0389 protein in the example of the present invention;
SEQ ID NO.2 is the amino acid sequence of the Rv1408 protein in the embodiment of the invention;
SEQ ID NO.3 is the amino acid sequence of the Rv2097c protein in the examples of the present invention.
Detailed Description
The invention discloses application of a product for detecting the level of an anti-Rv 0389 antibody, an anti-Rv 1408 antibody and/or an anti-Rv 2097c antibody in a sample in preparing a product for identifying, diagnosing and/or screening latent tuberculosis infection and/or active tuberculosis. Those skilled in the art can, with the benefit of this disclosure, suitably modify the process parameters to achieve this. It is to be particularly pointed out that all similar substitutes and modifications apparent to those skilled in the art are deemed to be included in the invention and that the relevant person can make modifications and appropriate alterations and combinations of what is described herein to make and use the technology without departing from the spirit and scope of the invention.
In the present invention, unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by one of ordinary skill in the art.
In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention will be further described in detail with reference to specific embodiments.
Example 1: sample collection and processing
The sample detected by the invention is serum, the collection method is that blood of a subject is collected on an empty stomach, a common biochemical test tube without anticoagulant is used, the sample is stood at room temperature and naturally solidified, and is centrifuged for 10 minutes at a speed of 3000 rpm Zhong Changwen, the serum is collected and split-packed in a freezing tube, and the freezing tube is placed in a low-temperature refrigerator at-80 ℃ for preservation and is used for experiments.
The samples used in the present invention are divided into two groups: a group of latent infections and active tuberculosis patients; the latent infection group refers to a patient without clinical complaints, and the TST experiment and the T-SPOT experiment are positive and the chest X-ray film is negative; the active tuberculosis patient group refers to the tuberculosis patients which are positive through smear or culture and are not or just beginning systematic chemical drug treatment; both groups were excluded from diabetes, HIV infection and other autoimmune diseases.
The latent infection group specimen used in the invention is from epidemiological investigation projects of epidemiology research laboratory of Beijing tuberculosis chest tumor research institute, the active tuberculosis patient group specimen is from inpatients in each disease area of Beijing tuberculosis hospital affiliated to the university of the capital medical science, the subject is approved by the ethics committee of Beijing tuberculosis chest hospital/Beijing tuberculosis chest tumor research institute of the university of the capital medical science, and all the study objects are informed consent.
Example 2: detection of samples using ELISA experiments
1. Various buffers, dilutions, reaction solutions and termination solutions required to establish ELSIA experiments:
(1) Coating buffer (pH 9.6,0.05mol/L carbonate buffer):
Na 2 CO 3 1.59g，NaHCO 3 2.93g of double distilled water is added to 1000ml, and the pH is adjusted to 9.6;
(2) PBS solution at pH 7.4:
NaCl 8.0g，KCl 0.2g，KH 2 PO 4 0.2g，Na 2 HPO 4 ·12H 2 o2.9 g, adding double distilled water to 1000ml, and adjusting pH to 7.4;
(3) PBST wash at ph 7.4:
tween-20 is added into 1000ml of PBS solution for 0.5ml, and the pH is adjusted to 7.4;
(4) Blocking solution (PBS solution ph7.4 containing skimmed milk powder):
5g of skimmed milk powder was added to 100ml of PBS solution;
(5) Substrate buffer: 0.2M NaH 2 PO 4 (28.4g/L)25.7ml，
0.1M citric acid (19.2 g/L) 24.3ml, and distilled water 50ml.
(6) TMB (tetramethylbenzidine) use solution TMB (10 mg/5ml absolute ethanol) 0.5ml substrate buffer (pH 5.5) 10ml 0.75% H 2 O 2 32μl；
(7) Termination liquid (2M H) 2 SO 4 )：21.32ml H 2 SO 4 ，178.68ml H 2 O。
(8) And (2) secondary antibody: horseradish peroxidase (HRP) -labeled goat anti-human IgG;
(9) 96-well elisa plate; nunc Incorporated (Thermomo, gebenhagen, denmark)
2. The detection step comprises:
(1) Coating: the Rv0389, rv1408 and Rv2097c antigens were dissolved in coating buffer (5 ug/ml), respectively; 100 ul/well was added to the 96-well ELISA plate at 4deg.C overnight;
(2) Washing the plate: PBST washing solution 300 ul/hole for 3min, washing 3 times;
(3) Closing: blocking the solution, 300 ul/hole, and incubating for 1h at room temperature;
(4) Washing the plate: 300 ul/hole of washing liquid, 3min, 3 times of washing;
(5) Adding serum: the serum to be tested is diluted according to the ratio of 1:400, 100 ul/hole is incubated for 1h at room temperature;
(6) Washing the plate: 300 ul/hole of washing liquid, 3min, 5 times of washing;
(7) Adding enzyme-labeled secondary antibodies: 100 ul/well of freshly diluted enzyme-labeled antibody (1:30000), incubated for 1h at room temperature;
(8) Washing the plate: 300 ul/hole of washing liquid, 3min, 5 times of washing;
(9) Color development: freshly prepared TMB color development solution, 100 ul/hole, incubate at room temperature in the dark for 5-10min;
(10) And (3) terminating: termination liquid 2M H 2 SO 4 50 ul/well;
(11) And (3) measuring: the microplate reader was adjusted to 450nm and the OD of each well was measured after zeroing the first blank PBS control well.
3. Result analysis and decision criteria:
drawing a ROC curve by using SPSS22.0 software, obtaining the specificities and sensitivities corresponding to different critical points according to coordinate values, and then calculating about dengue indexes (about dengue indexes = specificities + sensitivities-1), wherein the OD values of the critical points of the three antigens are respectively 0.291 for Rv0389, 0.283 for Rv1408 and 0.308 for Rv2097 c;
the results are shown in figure 1, and the results show that all three proteins have the effect of distinguishing latent tuberculosis infection from active tuberculosis.
Determination criteria:
and (3) using three proteins for combined detection, if at least 2 antibodies in the anti-Rv 0389 antibody, the anti-Rv 1408 antibody and/or the anti-Rv 2097c antibody are positive in the detection result of the sample to be detected, judging that the sample to be detected is positive in active tuberculosis, otherwise, judging that the sample to be detected is latent tuberculosis infection.
Example 3: specificity and sensitivity of methods for differential diagnosis of active tuberculosis patients and latent infectors using ELISA
92 parts of patient serum with clinical diagnosis of active tuberculosis and 93 parts of serum of latent infectious agents; the ELISA method in examples 1 and 2 was used to determine whether the test subjects were positive for active tuberculosis by the criteria of example 2, and the results are shown in FIG. 2, with an analytical specificity of 86.0% and a sensitivity of 71.7%. In FIG. 2, the abscissa 1-specificity represents the false positive rate, and the ordinate sensitivity represents the true positive rate.
The results prove that the invention detects the serum antibody response level of three different mycobacterium tuberculosis proteins, can better diagnose tuberculosis latent infection patients and active tuberculosis patients in a differential mode, and has higher sensitivity and better specificity.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Sequence listing
<110> Beijing chest Hospital affiliated with university of capital medical science
<120> use of Mycobacterium tuberculosis proteins for the preparation of a product for the diagnosis of tuberculosis latent infected persons and/or active tuberculosis
<130> None
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 419
<212> PRT
<213> Bacteria
<400> 1
Val Ile Asp Gly Trp Thr Glu Glu Gln His Glu Pro Thr Val Arg His
1 5 10 15
Glu Arg Pro Ala Ala Pro Gln Asp Val Arg Arg Val Met Leu Leu Gly
20 25 30
Ser Ala Glu Pro Ser Arg Glu Leu Ala Ile Ala Leu Gln Gly Leu Gly
35 40 45
Ala Glu Val Ile Ala Val Asp Gly Tyr Val Gly Ala Pro Ala His Arg
50 55 60
Ile Ala Asp Gln Ser Val Val Val Thr Met Thr Asp Ala Glu Glu Leu
65 70 75 80
Thr Ala Val Ile Arg Arg Leu Gln Pro Asp Phe Leu Val Thr Val Thr
85 90 95
Ala Ala Val Ser Val Asp Ala Leu Asp Ala Val Glu Gln Ala Asp Gly
100 105 110
Glu Cys Thr Glu Leu Val Pro Asn Ala Arg Ala Val Arg Cys Thr Ala
115 120 125
Asp Arg Glu Gly Leu Arg Arg Leu Ala Ala Asp Gln Leu Gly Leu Pro
130 135 140
Thr Ala Pro Phe Trp Phe Val Gly Ser Leu Gly Glu Leu Gln Ala Val
145 150 155 160
Ala Val His Ala Gly Phe Pro Leu Leu Val Ser Pro Val Ala Gly Val
165 170 175
Ala Gly Gln Gly Ser Ser Val Val Ala Gly Pro Asn Glu Val Glu Pro
180 185 190
Ala Trp Gln Arg Ala Ala Gly His Gln Val Gln Pro Gln Thr Gly Gly
195 200 205
Val Ser Pro Arg Val Cys Ala Glu Ser Val Val Glu Ile Glu Phe Leu
210 215 220
Val Thr Met Ile Val Val Cys Ser Gln Gly Pro Asn Gly Pro Leu Ile
225 230 235 240
Glu Phe Cys Ala Pro Ile Gly His Arg Asp Ala Asp Ala Gly Glu Leu
245 250 255
Glu Ser Trp Gln Pro Gln Lys Leu Ser Thr Ala Ala Leu Asp Ala Ala
260 265 270
Lys Ser Ile Ala Ala Arg Ile Val Lys Ala Leu Gly Gly Arg Gly Val
275 280 285
Phe Gly Val Glu Leu Met Ile Asn Gly Asp Glu Val Tyr Phe Ala Asp
290 295 300
Val Thr Val Cys Pro Ala Gly Ser Ala Trp Val Thr Val Arg Ser Gln
305 310 315 320
Arg Leu Ser Val Phe Glu Leu Gln Ala Arg Ala Ile Leu Gly Leu Ala
325 330 335
Val Asp Thr Leu Met Ile Ser Pro Gly Ala Ala Arg Val Ile Asn Pro
340 345 350
Asp His Thr Ala Gly Arg Ala Ala Val Gly Ala Ala Pro Pro Ala Asp
355 360 365
Ala Leu Thr Gly Ala Leu Gly Val Pro Glu Ser Asp Val Val Ile Phe
370 375 380
Gly Arg Gly Leu Gly Val Ala Leu Ala Thr Ala Pro Glu Val Ala Ile
385 390 395 400
Ala Arg Glu Arg Ala Arg Glu Val Ala Ser Arg Leu Asn Val Pro Asp
405 410 415
Ser Arg Glu
<210> 2
<211> 232
<212> PRT
<213> Bacteria
<400> 2
Val Ser Leu Met Ala Gly Ser Thr Gly Gly Pro Leu Ile Ala Pro Ser
1 5 10 15
Ile Leu Ala Ala Asp Phe Ala Arg Leu Ala Asp Glu Ala Ala Ala Val
20 25 30
Asn Gly Ala Asp Trp Leu His Val Asp Val Met Asp Gly His Phe Val
35 40 45
Pro Asn Leu Thr Ile Gly Leu Pro Val Val Glu Ser Leu Leu Ala Val
50 55 60
Thr Asp Ile Pro Met Asp Cys His Leu Met Ile Asp Asn Pro Asp Arg
65 70 75 80
Trp Ala Pro Pro Tyr Ala Glu Ala Gly Ala Tyr Asn Val Thr Phe His
85 90 95
Ala Glu Ala Thr Asp Asn Pro Val Gly Val Ala Arg Asp Ile Arg Ala
100 105 110
Ala Gly Ala Lys Ala Gly Ile Ser Val Lys Pro Gly Thr Pro Leu Glu
115 120 125
Pro Tyr Leu Asp Ile Leu Pro His Phe Asp Thr Leu Leu Val Met Ser
130 135 140
Val Glu Pro Gly Phe Gly Gly Gln Arg Phe Ile Pro Glu Val Leu Ser
145 150 155 160
Lys Val Arg Ala Val Arg Lys Met Val Asp Ala Gly Glu Leu Thr Ile
165 170 175
Leu Val Glu Ile Asp Gly Gly Ile Asn Asp Asp Thr Ile Glu Gln Ala
180 185 190
Ala Glu Ala Gly Val Asp Cys Phe Val Ala Gly Ser Ala Val Tyr Gly
195 200 205
Ala Asp Asp Pro Ala Ala Ala Val Ala Ala Leu Arg Arg Gln Ala Gly
210 215 220
Ala Ala Ser Leu His Leu Ser Leu
225 230
<210> 3
<211> 452
<212> PRT
<213> Bacteria
<400> 3
Val Gln Arg Arg Ile Met Gly Ile Glu Thr Glu Phe Gly Val Thr Cys
1 5 10 15
Thr Phe His Gly His Arg Arg Leu Ser Pro Asp Glu Val Ala Arg Tyr
20 25 30
Leu Phe Arg Arg Val Val Ser Trp Gly Arg Ser Ser Asn Val Phe Leu
35 40 45
Arg Asn Gly Ala Arg Leu Tyr Leu Asp Val Gly Ser His Pro Glu Tyr
50 55 60
Ala Thr Ala Glu Cys Asp Ser Leu Val Gln Leu Val Thr His Asp Arg
65 70 75 80
Ala Gly Glu Trp Val Leu Glu Asp Leu Leu Val Asp Ala Glu Gln Arg
85 90 95
Leu Ala Asp Glu Gly Ile Gly Gly Asp Ile Tyr Leu Phe Lys Asn Asn
100 105 110
Thr Asp Ser Ala Gly Asn Ser Tyr Gly Cys His Glu Asn Tyr Leu Ile
115 120 125
Val Arg Ala Gly Glu Phe Ser Arg Ile Ser Asp Val Leu Leu Pro Phe
130 135 140
Leu Val Thr Arg Gln Leu Ile Cys Gly Ala Gly Lys Val Leu Gln Thr
145 150 155 160
Pro Lys Ala Ala Thr Tyr Cys Leu Ser Gln Arg Ala Glu His Ile Trp
165 170 175
Glu Gly Val Ser Ser Ala Thr Thr Arg Ser Arg Pro Ile Ile Asn Thr
180 185 190
Arg Asp Glu Pro His Ala Asp Ala Glu Lys Tyr Arg Arg Leu His Val
195 200 205
Ile Val Gly Asp Ser Asn Met Ser Glu Thr Thr Thr Met Leu Lys Val
210 215 220
Gly Thr Ala Ala Leu Val Leu Glu Met Ile Glu Ser Gly Val Ala Phe
225 230 235 240
Arg Asp Phe Ser Leu Asp Asn Pro Ile Arg Ala Ile Arg Glu Val Ser
245 250 255
His Asp Val Thr Gly Arg Arg Pro Val Arg Leu Ala Gly Gly Arg Gln
260 265 270
Ala Ser Ala Leu Asp Ile Gln Arg Glu Tyr Tyr Thr Arg Ala Val Glu
275 280 285
His Leu Gln Thr Arg Glu Pro Asn Ala Gln Ile Glu Gln Val Val Asp
290 295 300
Leu Trp Gly Arg Gln Leu Asp Ala Val Glu Ser Gln Asp Phe Ala Lys
305 310 315 320
Val Asp Thr Glu Ile Asp Trp Val Ile Lys Arg Lys Leu Phe Gln Arg
325 330 335
Tyr Gln Asp Arg Tyr Asp Met Glu Leu Ser His Pro Lys Ile Ala Gln
340 345 350
Leu Asp Leu Ala Tyr His Asp Ile Lys Arg Gly Arg Gly Ile Phe Asp
355 360 365
Leu Leu Gln Arg Lys Gly Leu Ala Ala Arg Val Thr Thr Asp Glu Glu
370 375 380
Ile Ala Glu Ala Val Asp Gln Pro Pro Gln Thr Thr Arg Ala Arg Leu
385 390 395 400
Arg Gly Glu Phe Ile Ser Ala Ala Gln Glu Ala Gly Arg Asp Phe Thr
405 410 415
Val Asp Trp Val His Leu Lys Leu Asn Asp Gln Ala Gln Arg Thr Val
420 425 430
Leu Cys Lys Asp Pro Phe Arg Ala Val Asp Glu Arg Val Lys Arg Leu
435 440 445
Ile Ala Ser Met
450
Claims (4)
1. Use of a product for detecting levels of an anti-Rv 0389 antibody, an anti-Rv 1408 antibody and an anti-Rv 2097c antibody in a sample for the preparation of a product for the identification, diagnosis and/or screening of tuberculosis latent infection;
the sample is serum.
2. A use according to claim 1, wherein the products for detecting levels of anti-Rv 0389 antibodies, anti-Rv 1408 antibodies and anti-Rv 2097c antibodies in a sample comprise Rv0389 protein, rv1408 protein and Rv2097c protein.
3. The use according to claim 2, wherein the Rv0389 protein is shown in SEQ ID No. 1; the Rv1408 protein is shown in SEQ ID NO. 2; the Rv2097c protein is shown as SEQ ID NO. 3.
4. The use according to any one of claims 1 to 3, wherein the method of detection comprises an enzyme-linked immunosorbent assay, an agglutination assay, a precipitation assay, an E-garland assay, a small phagocytosis assay, an immunofluorescence assay, a colloidal gold immunochromatography assay, a spot gold immunodiafiltration assay and/or an electrochemiluminescence assay.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010371676.7A CN111551742B (en) | 2016-12-30 | 2016-12-30 | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010371676.7A CN111551742B (en) | 2016-12-30 | 2016-12-30 | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis |
| CN201611257494.7A CN108267588B (en) | 2016-12-30 | 2016-12-30 | Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611257494.7A Division CN108267588B (en) | 2016-12-30 | 2016-12-30 | Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111551742A CN111551742A (en) | 2020-08-18 |
| CN111551742B true CN111551742B (en) | 2023-06-16 |
Family
ID=62754583
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010371840.4A Active CN111521820B (en) | 2016-12-30 | 2016-12-30 | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis |
| CN201611257494.7A Active CN108267588B (en) | 2016-12-30 | 2016-12-30 | Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis |
| CN202010371676.7A Active CN111551742B (en) | 2016-12-30 | 2016-12-30 | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010371840.4A Active CN111521820B (en) | 2016-12-30 | 2016-12-30 | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis |
| CN201611257494.7A Active CN108267588B (en) | 2016-12-30 | 2016-12-30 | Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN111521820B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103698511A (en) * | 2013-11-25 | 2014-04-02 | 广东体必康生物科技有限公司 | Application of mycobacterium tuberculosis protein in preparation of products used for diagnosis of latent tuberculosis infection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012202486B2 (en) * | 1999-07-13 | 2014-08-14 | Statens Serum Institut | Tuberculosis vaccine and diagnostics based on the Mycobacterium tuberculosis esat-6 gene family |
| JP4623825B2 (en) * | 1999-12-16 | 2011-02-02 | 協和発酵バイオ株式会社 | Novel polynucleotide |
| EP2196473A1 (en) * | 2001-07-04 | 2010-06-16 | Health Protection Agency | Mycobacterial antigens expressed during latency |
| US7282491B2 (en) * | 2002-12-06 | 2007-10-16 | Cornell Research Foundation, Inc. | Prokaryotic proteasomal proteases of Mycobacterium tuberculosis (MTB) as targets for antibiotic therapy |
| US20060182685A1 (en) * | 2004-09-04 | 2006-08-17 | Bishai William R | Hollow fiber technique for in vivo study of cell populations |
| CA2603356A1 (en) * | 2005-03-31 | 2006-10-05 | Leiden University Medical Center | Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease |
| EP2305701A1 (en) * | 2005-07-01 | 2011-04-06 | Forsyth Dental Infirmary for Children | Tuberculosis antigen detection assays and vaccines |
| WO2007131291A1 (en) * | 2006-05-16 | 2007-11-22 | Proteome Systems Limited | Methods of diagnosis and treatment of m. tuberculosis infection and reagents therefore |
| CN101294964B (en) * | 2007-11-27 | 2012-06-27 | 复旦大学附属华山医院 | Reagent and method for detecting active tuberculosis and tuberculosis dormant infection |
| GB0906215D0 (en) * | 2009-04-09 | 2009-05-20 | Lalvani Ajit | Diagnostic test |
| AR081022A1 (en) * | 2011-05-06 | 2012-05-30 | Inst Nac De Tecnologia Agropecuaria Int A | METHOD FOR DETECTING ANTIGENS FROM MYCOBACTERIUM TUBERCULOSIS |
| CN102590502B (en) * | 2012-01-11 | 2014-07-02 | 北京市结核病胸部肿瘤研究所 | Kit for auxiliary diagnosis of tuberculosis patients |
| CN103698530B (en) * | 2013-11-25 | 2015-08-19 | 广东体必康生物科技有限公司 | The purposes of Mycobacterium tuberculosis albumen in the phthisical product of preparation diagnostic activities |
| CN103698531B (en) * | 2013-11-25 | 2015-10-14 | 广东体必康生物科技有限公司 | The purposes of Rv1860, Rv0173 and/or Rv1812c albumen in the phthisical product of preparation diagnostic activities |
| CN104805063A (en) * | 2014-01-24 | 2015-07-29 | 中国人民解放军第三〇九医院 | Mycobacterium tuberculosis latent infection related proteins, preparation and applications thereof |
| CN105588944B (en) * | 2016-02-25 | 2017-05-24 | 首都医科大学附属北京胸科医院 | Application of AGP1, SERPINA3 and CDH1 content detection system in screening active tuberculosis patients |
-
2016
- 2016-12-30 CN CN202010371840.4A patent/CN111521820B/en active Active
- 2016-12-30 CN CN201611257494.7A patent/CN108267588B/en active Active
- 2016-12-30 CN CN202010371676.7A patent/CN111551742B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103698511A (en) * | 2013-11-25 | 2014-04-02 | 广东体必康生物科技有限公司 | Application of mycobacterium tuberculosis protein in preparation of products used for diagnosis of latent tuberculosis infection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111521820B (en) | 2023-06-16 |
| CN111551742A (en) | 2020-08-18 |
| CN111521820A (en) | 2020-08-11 |
| CN108267588A (en) | 2018-07-10 |
| CN108267588B (en) | 2020-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haque et al. | Diagnosis of amebiasis in Bangladesh | |
| Mukundan et al. | Rapid detection of Mycobacterium tuberculosis biomarkers in a sandwich immunoassay format using a waveguide-based optical biosensor | |
| Chan et al. | Diagnosis of tuberculosis by a visually detectable immunoassay for lipoarabinomannan | |
| JP3969722B2 (en) | Candida detection | |
| Feng et al. | Enhanced serodiagnostic utility of novel Mycobacterium tuberculosis polyproteins | |
| Vadivelu et al. | Serodiagnosis of melioidosis in Malaysia | |
| KR101775851B1 (en) | Method and kit for diagnosis of tuberculosis based on Mycobacterium tuberculosis antigen-specific antibody reaction | |
| CN111551741B (en) | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis | |
| JP4419020B2 (en) | Method for detecting Mycobacterium tuberculosis antigen in body fluid | |
| Ng et al. | Serodiagnosis of pericardial tuberculosis | |
| McConkey S et al. | Evaluation of a rapid-format antibody test and the tuberculin skin test for diagnosis of tuberculosis in two contrasting endemic settings | |
| Abeijon et al. | Novel antigen detection assay to monitor therapeutic efficacy of visceral leishmaniasis | |
| Harinath et al. | A cocktail of affinity-purified antibodies reactive with diagnostically useful mycobacterial antigens ES-31, ES-43, and EST-6 for detecting the presence of Mycobacterium tuberculosis | |
| CN111551742B (en) | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis | |
| Liu et al. | Utility of urine lipoarabinomannan (LAM) in diagnosing mycobacteria infection among hospitalized HIV-positive patients | |
| KR102132964B1 (en) | Method for Diagnosing Scrub Typhus Using Exosome derived from Orientia tsutsugamushi | |
| CN105388291B (en) | Gamma delta T cell surface activation molecule and kit for quickly diagnosing active tuberculosis | |
| Tabasi et al. | Development of an indirect ELISA based on whole cell Brucella abortus S99 lysates for detection of IgM anti-Brucella antibodies in human serum | |
| Sarkari et al. | A comparative study of antigen and antibody detection in visceral leishmaniasis using serum and urine-based ELISA | |
| CN107202882B (en) | Purposes of the Rv0440 albumen in diagnosis latency/active tuberculosis | |
| Almeida et al. | Humoral immune responses of tuberculosis patients in Brazil indicate recognition of Mycobacterium tuberculosis MPT-51 and GlcB | |
| Ahmadi et al. | Comparative Evaluation of Specific Antibody against Mycobacterium tuberculosis ESAT-6 Recombinant Antigen in Healthy Subject with Positive and Negative Skin Test | |
| KR20160139888A (en) | Method and kit for diagnosis of tuberculosis based on Mycobacterium tuberculosis antigen-specific antibody reaction | |
| CN106814194B (en) | A kind of kit for distinguishing activity and latent tuberculosis infects | |
| Shende et al. | A low molecular weight ES-20 protein released in vivo and in vitro with diagnostic potential in lymph node tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |